CJC-1295 is a synthetic long-acting growth-hormone-releasing hormone (GHRH) analog. Like ipamorelin, it has been heavily marketed in the research-peptide and wellness market — typically paired with ipamorelin in 'GH-restoration' protocols at peptide clinics.
The regulatory picture matches the rest of the research-peptide cohort. CJC-1295 was named in Health Canada's public advisory against unauthorized injectable peptides; sits on the FDA Section 503A bulks list discussions; and was on the ProPublica-reported list of injectable peptides covered by the FDA's 2023 effective ban. State medical board enforcement against peptide clinics has included CJC-1295 in case files.
Clinical evidence for advertised wellness claims remains thin. Stories here cover regulatory action and any registered human trials. See #ipamorelin, #sermorelin, and #tesamorelin for adjacent tags.
A 2026 scoping review in the Journal of Cachexia, Sarcopenia and Muscle catalogs peptides studied as therapeutic candidates and biomarkers in skeletal muscle wasting — covering sarcopenia, cancer cachexia, and ICU-related atrophy. The review documents MIF1/MIF2 myostatin peptide inhibitors, cachexia-targeting platform peptides, and the broader role of GH-axis peptides (CJC-1295, ipamorelin, tesamorelin) in muscle homeostasis. The clinical urgency lands harder now than it did pre-2024: Nature Reviews Endocrinology recently flagged sarcopenia and frailty as under-recognized GLP-1 receptor agonist side effects, with up to 40% of GLP-1-induced weight loss attributable to lean mass in the highest-loss patients. The review surfaces non-GLP-1 peptide candidates that could be paired with incretin therapy to protect muscle.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'